Chairs/Moderators: Stephanie Berg, DO & Adam Singer, MD

Awards Presentation: Dan Geynisman, MD

Poster Ad #1: Cabozantinib in Patients (Pts) With Non-Locally Pretreated Brain Metastases (BM) From Renal Cell Carcinoma (RCC): Results From the Multicenter CABRAMET Phase II Trial: Sylvie Negrier, MD, PhS

Poster Ad #2: Association Between Wildfire-Dominated PM2.5 Exposure and Renal Cell Carcinoma Survival in California: Shuchi Gulati, MD, MSc

Poster Ad #3: AI-Driven Multiplex Immunofluorescence Analysis of the Tumor Immune Microenvironment to Predict Immunotherapy Response in Clear Cell Renal Cell Carcinoma: Yuanquan Yang, MD, PhD

Poster Ad #4: Strategic Trimodal Therapy Enhances Radiation-Induced Abscopal Response in Renal Cancer: Krishnendu Pal, PhD

Abstract Presentation #1: A Multi-Institution Analysis of Outcomes for 190 Patients With Metastatic Chromophobe Renal Cell Carcinoma With and Without Sarcomatoid Features: Sahil Doshi, MD

Abstract Presentation #2: Outcomes of Patients With Fumarate Hydratase–Deficient Renal Cell Carcinoma Treated With Cabozantinib + Nivolumab: Maria Carlo, MD

Abstract Presentation #3: Exploring the Impact of Combined Anti-Angiogenic and Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma Metastases: Stefan Maksimovic, MD

Abstract Presentation #4: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Monty Pal, MD, FASCO

Q & A